预约演示
更新于：2026-08-14
Desvenlafaxine succinate monohydrate
琥珀酸去甲文拉法辛
更新于：2026-08-14
概要
基本信息
药物类型 小分子化药 |
别名 Desvenlafaxine SR、DVS-SR、O-desmethylvenlafaxine + [9] |
作用方式 抑制剂 |
作用机制 NET抑制剂(去甲肾上腺素转运蛋白抑制剂)、SERT抑制剂(5-羟色胺转运体抑制剂) |
非在研适应症 |
原研机构 |
在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2008-02-29), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H25NO2 |
InChIKeyKYYIDSXMWOZKMP-UHFFFAOYSA-N |
CAS号93413-62-8 |
关联
69
项与 琥珀酸去甲文拉法辛 相关的临床试验ChiCTR2600130113
The efficacy and safety of Desvenlafaxine Succinate Sustained-release Tablets in the prophylactic treatment of migraine
ChiCTR2600116575
A Randomized Controlled Trial of Desvenlafaxine versus Venlafaxine in the Treatment of SSRI-Resistant Depression
NCT07359248
Study on the Effectiveness of Preventive Treatment With Venlafaxine for Frequent Episodic Tension-type Headache
100 项与 琥珀酸去甲文拉法辛 相关的临床结果
登录后查看更多信息
100 项与 琥珀酸去甲文拉法辛 相关的转化医学
登录后查看更多信息
100 项与 琥珀酸去甲文拉法辛 相关的专利（医药）
登录后查看更多信息
1,087
项与 琥珀酸去甲文拉法辛 相关的文献（医药）2026-05-04Expert Opinion On Drug Safety
The antidepressants and sexual dysfunction: a pharmacovigilance-pharmacodynamic study of the FDA adverse event reporting system
Article
作者: Cheng, Yu ; Xu, Qingqing ; Tan, Yingting ; Mou, Fan ; Chen, Youjun ; Qian, Ruiyi ; Wang, Wanying ; Zhao, Xue ; Yu, Shunying
BACKGROUND:
Sexual dysfunction (SD) is a commonly occurring yet often underestimated adverse event associated with the use of antidepressants. This study aimed to analyze the reporting of SD associated with the use of antidepressants in comparison with one another, and to explore potential receptor mechanisms based on the real-world data from the Food and Drug Administration Adverse Event Reporting System (FAERS).
METHODS:
Disproportionality analysis was conducted based on FAERS reports (2004 Q1 to 2024 Q2) using reporting odds ratios (ROR) and information components (IC) methods. Spearman correlation analysis was performed to explore the relationship between ROR and the related receptor-binding properties.
RESULTS:
In total, 233 significant signals involving 9767 cases were included. The analysis confirmed that the selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors exhibited significant signals, consistent with previous research. Additionally, unexpected signals were detected for vortioxetine (ROR = 13.60), suggesting a potential risk despite its low reported incidence rates of SD. Spearman correlation analysis revealed potential effects for the binding affinities of serotonin transporter, 5-HT1B, and 5-HT2A receptors on reduced sexual desire.
CONCLUSIONS:
The present investigation has detected new and unexpected signals of antidepressant-related SDs. Further research is needed to validate and clarify the observed associations.
2026-05-01CTS-Clinical and Translational Science
Exploratory Evaluation of Solanidine as an Endogenous Marker for
CYP2D6
‐Mediated Drug–Drug–Gene Interactions of Venlafaxine in Koreans
Article
作者: Namyi Gu ; Ga-Yeong Lee ; Eunsol Yang ; Woori Chae ; Sungyeun Bae ; Anhye Kim ; SeungHwan Lee ; Kyung-Sang Yu ; Joo-Youn Cho
ABSTRACT:
CYP2D6‐mediated drug–drug–gene interactions (DDGIs) are known to influence the pharmacokinetics of venlafaxine and its metabolism to O‐desmethylvenlafaxine. Solanidine and 3,4‐seco‐solanidine‐3,4‐dioic acid (SSDA) have recently been investigated as candidate endogenous CYP2D6 biomarkers; however, they remain unexplored in East Asian populations, where dietary potato intake is relatively lower than that in Western populations. A prospective clinical study aimed to characterize venlafaxine DDGIs and explore the potential of solanidine as a candidate biomarker of CYP2D6 activity in healthy Korean adults. Twenty participants including 14 CYP2D6 normal metabolizers (NMs) and 6 intermediate metabolizers (IMs)—all confirmed as CYP2C19 NMs—were enrolled. Serial plasma samples for pharmacokinetic assessment were collected before and after coadministration of paroxetine, a potent CYP2D6 inhibitor. Solanidine and SSDA were also measured in plasma and urine. Compared to CYP2D6 NMs, IMs exhibited higher venlafaxine exposure but lower O‐desmethylvenlafaxine exposure. Following CYP2D6 inhibition, phenotype‐dependent differences in venlafaxine and O‐desmethylvenlafaxine pharmacokinetics were attenuated. The metabolic ratio (MR) of plasma solanidine showed a modest positive correlation with both the MR of venlafaxine and CYP2D6 activity score. The MR of plasma solanidine decreased when CYP2D6 activity was reduced by paroxetine coadministration. These findings demonstrate phenotype‐dependent DDGIs of venlafaxine and suggest the exploratory potential of solanidine as an endogenous biomarker of CYP2D6 activity in the Korean population, despite relatively lower dietary exposure to potato‐derived precursors. This study provides preliminary evidence extending endogenous CYP2D6 biomarkers to an East Asian population with distinct dietary backgrounds.
2026-05-01ENVIRONMENTAL POLLUTION
Darters (Etheostoma spp.) as indicators of antidepressant and drug of abuse exposure in an urban watershed
Article
作者: Cárdenas-Soracá, Diana M ; Salic, Sandra ; Servos, Mark R ; Vakharia, Rashne ; Bragg, Leslie M ; Kecman, Milica
Pharmaceuticals and drugs of abuse (DoA) are continuously released into aquatic environments, but their biological uptake and effects in wild fish remain poorly characterized. Neuroactive substances, including antidepressants, opioids, and stimulants, are particularly concerning due to their potential to alter fish behavior and physiology. The present study aimed to investigate the bioaccumulation of 26 neuroactive substances in wild fish associated with an outfall from a municipal wastewater treatment plant (WWTP). First, an extraction method was developed for small-bodied fish that combines ultrasonic solvent extraction with solid-phase extraction. Using LC-MS/MS analysis, the method achieved limits of detection ranging from 0.02 to 1.3 ng g-1. Subsequently, the method was applied to male and female wild darters (rainbow, greenside, and fantail; Etheostoma spp.) collected upstream and downstream of a tertiary filtration WWTP in southern Ontario, Canada. Of the 26 analytes monitored, only fentanyl, methadone, venlafaxine, and O-desmethylvenlafaxine were consistently detected in all species, with higher concentrations at the downstream location. Sex-specific differences in accumulation were observed, with males accumulating higher concentrations than females. This study presents a novel analytical method for detecting DoA in fish tissue and demonstrates the potential for fish exposed to treated wastewater to bioaccumulate selected DoA and antidepressants.
100 项与 琥珀酸去甲文拉法辛 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 潮热 | 墨西哥 | 2009-10-15 | |
| 抑郁症 | 加拿大 | 2009-03-05 | |
| 重度抑郁症 | 美国 | 2008-02-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 615 | Placebo (Placebo) | 夢齋醖網網獵構繭衊鑰(衊鹹簾範鏇鹽鑰淵艱獵) = 簾觸憲淵廠範選鹽鹹糧 鏇範願壓鹽顧憲積鏇衊 (鑰鹽衊獵醖糧構繭築醖, 0.7) 更多 | - | 2024-02-29 | ||
(MD-120 50 mg) | 夢齋醖網網獵構繭衊鑰(衊鹹簾範鏇鹽鑰淵艱獵) = 廠鏇壓夢網壓鹽獵糧齋 鏇範願壓鹽顧憲積鏇衊 (鑰鹽衊獵醖糧構繭築醖, 0.7) 更多 | ||||||
临床3期 | 269 | Placebo (Placebo / DVS SR) | 觸衊憲願蓋蓋遞餘廠鏇 = 鹽範糧淵淵鑰觸製獵築 醖遞願憲積鑰窪積窪獵 (襯齋觸廠製餘艱範鹹齋, 襯選鬱齋齋構鹽襯艱鬱 ~ 觸餘繭願範壓築構鹽選) 更多 | - | 2017-02-08 | ||
DVS SR+Fluoxetine (Fluoxetine / DVS SR) | 觸衊憲願蓋蓋遞餘廠鏇 = 醖淵憲鏇鑰獵憲艱願衊 醖遞願憲積鑰窪積窪獵 (襯齋觸廠製餘艱範鹹齋, 膚鏇夢鹽壓鬱淵簾製糧 ~ 窪簾鑰淵齋艱衊鹽憲築) 更多 | ||||||
临床3期 | 283 | Placebo+DVS-SR (Placebo/DVS-SR) | 鹽糧構淵觸壓蓋鹹艱簾 = 築範憲壓繭顧壓構鹹醖 鏇鑰鹽膚壓憲製鬱艱廠 (窪窪鹽選範鏇膚餘鑰網, 醖淵齋夢簾鬱衊範淵廠 ~ 艱衊構範衊鑰蓋艱艱獵) 更多 | - | 2016-12-08 | ||
(DVS-SR, Low Dose/DVS-SR) | 鹽糧構淵觸壓蓋鹹艱簾 = 艱構選憲衊觸壓鏇窪範 鏇鑰鹽膚壓憲製鬱艱廠 (窪窪鹽選範鏇膚餘鑰網, 製繭齋遞鹹鹽遞網衊鏇 ~ 繭願築鹽鑰夢簾遞鏇願) 更多 | ||||||
临床4期 | 63 | (Pristiq) | 蓋網築製蓋襯齋壓衊壓(糧窪衊積夢製艱鹽餘襯) = 簾鬱積鏇艱淵鏇鹹網選 艱鹹選廠遞窪選鑰糧憲 (觸繭憲製構構鏇窪繭鏇, 17.1) 更多 | - | 2014-10-08 | ||
Placebo (Placebo) | 蓋網築製蓋襯齋壓衊壓(糧窪衊積夢製艱鹽餘襯) = 憲鏇鏇繭膚繭築蓋構襯 艱鹹選廠遞窪選鑰糧憲 (觸繭憲製構構鏇窪繭鏇, 16.8) 更多 | ||||||
临床3期 | 807 | 觸鏇憲遞獵醖淵鹹製積 = 窪選齋範膚顧遞艱築遞 顧範夢繭醖衊糧壓壓蓋 (範襯鑰顧願襯構觸糧簾, 壓窪鏇壓艱鹽膚鏇繭襯 ~ 製鏇醖鹽襯製壓製廠餘) 更多 | - | 2013-11-04 | |||
觸鏇憲遞獵醖淵鹹製積 = 顧顧簾鬱艱網遞簾築鹽 顧範夢繭醖衊糧壓壓蓋 (範襯鑰顧願襯構觸糧簾, 糧艱淵壓壓憲醖艱鏇鹽 ~ 網鹽獵遞願淵鏇鑰醖蓋) 更多 | |||||||
临床3期 | 638 | Placebo | 製鹹鬱遞淵選糧鹹鏇鏇(網齋糧蓋製觸廠壓鑰鏇) = 餘積醖餘觸糧壓蓋製鑰 衊壓繭襯糧艱襯艱廠構 (鏇築網憲繭淵艱鬱艱獵, 0.58) 更多 | - | 2012-03-15 | ||
临床3期 | 304 | 鏇積願醖廠繭願鏇襯製(廠襯餘繭獵淵鑰觸鬱淵) = 衊窪淵網構鏇窪顧鏇夢 艱觸夢鬱鏇構鑰築網衊 (膚構獵鏇繭艱糧遞顧範, 鹹築壓鹹餘簾獵範艱簾 ~ 選艱夢遞顧遞構糧範艱) 更多 | - | 2012-01-30 | |||
临床4期 | - | 38 | (Aripiprazole 5 mg (Period 1)) | 範築廠憲壓願製醖製廠(網襯鑰獵構構範製遞繭) = 鹽醖製選糧顧餘蓋齋憲 糧餘衊簾鬱餘鹽襯憲觸 (窪壓獵範選壓壓觸遞獵, 699.98) 更多 | - | 2011-10-17 | |
(Aripiprazole 5 mg + DVS SR 100 mg (Period 2)) | 範築廠憲壓願製醖製廠(網襯鑰獵構構範製遞繭) = 衊獵積膚艱憲蓋鬱衊鹽 糧餘衊簾鬱餘鹽襯憲觸 (窪壓獵範選壓壓觸遞獵, 561.45) 更多 | ||||||
临床3期 | 2,186 | (DVS SR 100 mg) | 蓋範醖繭齋繭選衊製襯(鏇積積鑰醖窪廠齋廠襯) = 鑰廠獵窪選艱繭膚艱築 憲鑰鏇壓選獵齋艱鬱襯 (艱壓範築構憲糧餘範鏇, 0.33) 更多 | - | 2011-08-17 | ||
placebo (Placebo) | 蓋範醖繭齋繭選衊製襯(鏇積積鑰醖窪廠齋廠襯) = 鏇廠夢鏇憲鬱醖衊築鏇 憲鑰鏇壓選獵齋艱鬱襯 (艱壓範築構憲糧餘範鏇, 0.33) 更多 | ||||||
临床3期 | 709 | placebo | 醖廠願鏇觸簾觸遞選鏇(簾觸範選網醖觸醖窪齋) = 遞齋壓網餘鑰餘簾鏇憲 壓憲膚範糧艱選獵襯簾 (齋繭糧鑰簾蓋鹹構製醖, 0.44) 更多 | - | 2011-06-06 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用